We are proud to announce that we have received FDA Breakthrough Device Designation for OncobiotaLUNG! The OncobiotaLUNG assay is the first blood microbiome-driven liquid biopsy with proven effectiveness, including identifying cancer in its earliest stages. Breakthrough device designation validates Micronoma’s aim to improve the current standard of care for patients exhibiting lung nodules, using microbial biomarkers to detect lung carcinomas as early as stage I disease. Read more HERE. https://bit.ly/3GVY6wg
关于我们
Micronoma is the first cancer-detection company using liquid biopsy technology to detect and predict cancer by interrogating the microbial signal with clinical-grade accuracy at an early stage of the disease. Micronoma was founded by leaders in microbiome research, and committed to improving the lives of all involved in cancer diagnosis. The company started in 2019 and is headquartered in San Diego, California.
- 网站
-
https://www.micronoma.com
Micronoma的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Diego
- 类型
- 私人持股
- 创立
- 2019
地点
-
主要
获取路线
US，San Diego